Wyeth dumps once-promising Curis collaboration

Back in 2004, Wyeth considered a project with Curis to develop small molecule and protein Hedgehog agonists--which promised new therapies for stroke and cardiovascular ailments--worth potentially more than $170 million in milestone payments.

That was then.

This morning, Curis announced that Wyeth is pulling out of the pact. "Our speculation is that Wyeth has decided to re-prioritize," a Curis spokesman told the Boston Globe. Curis pocketed a $3 million upfront payment in the Wyeth deal. Since then, Curis has repositioned itself as well, focusing on new cancer therapies.

- see this release from Curis
- read the story in the Boston Globe

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.